^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    amelimumab (SY101)

    i
    Other names: SY101
    Associations

    News

    Trials
    Company:
    Tasly
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies. (PubMed, Ther Adv Med Oncol)
    The Ametumumab was well tolerated and safe in patients with advanced solid malignancies, exhibiting minimal immunogenicity, a long half-life, high levels of drug exposure in the blood, and preliminary effectiveness. The trial was registered with CTR20170343 on 10 April 2017, The China Center for Drug Evaluation.
    P1 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    amelimumab (SY101)
    almost2years
    A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer (clinicaltrials.gov)
    P2b, N=84, Not yet recruiting, Shanghai Celfuture Biotech Co., Ltd.
    New P2b trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
    |
    KRAS wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • amelimumab (SY101)